Global Crohn’s Disease Market – Size, Share and Forecast (2019-2026)

SKU: DPH8 | Published On: 2019-04-09 | Available Formats

Global Crohn’s Disease Therapeutics Market Overview

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the digestive tract, which can lead to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Crohn’s disease is caused by a combination of factors involving genetics, the environment, and an overactive immune system. It is not caused by something you ate or your diet. Crohn's drug treatment includes antibiotics, aminosalicylates (5-ASAs), corticosteroids, immune modifiers (immunomodulators) and biologic therapies (biologics). In some cases, surgery may also be necessary for patients.

The global Crohn’s disease therapeutics market was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period.


Global Crohn’s Disease Therapeutics Market – Market Dynamics

The increasing prevalence of inflammatory bowel disease (IBD) is one of the key factor driving the global Crohn’s disease therapeutics market.

For instance, according to World Health Organization (WHO), colder-climate regions and urban areas have a greater rate of IBD than those of warmer climates and rural areas. Globally, the incidence of IBD is approximately 0.5-24.5 cases per 100,000 for ulcerative colitis and 0.1-16 cases per 100,000 for Crohn disease. The prevalence for IBD is 396 cases per 100,000 persons annually. WHO’s regional analysis on IBD incidence states approximately 1.6 million Americans are suffering from Crohn’s disease or ulcerative colitis. 70,000 new cases of IBD are diagnosed in the US each year.



Global Crohn’s Disease Therapeutics Market – Segment Analysis

Based on drug class the global market for Crohn’s disease therapeutics is broadly segmented as anti-diarrheal, anti-inflammatory drugs, immunosuppressors, antibiotics, biologics, and pain relievers.

Currently, biologics is the dominant segment, and it accounts for approximately XX% of the market. The predominant market of biologics is mainly due to the regulatory approval for novel biologics and the recent surge in strategic alliances between companies related to biologics used for the treatment of Crohn’s disease.

For instance, in April 2018, Mylan N.V., partnered with Fujifilm Kyowa Kirin Biologics Co., Ltd. to commercialize Fujifilm’s Humira (adalimumab) biosimilar. Mylan will leverage its regulatory platform to seek approval and commercialize the product in Europe.

In September 2016, Janssen Biotech, Inc., received the U.S. Food and Drug Administration (FDA) approval for STELARA (ustekinumab) for the treatment of moderately to severely active Crohn’s disease in adults (18 years or older). STELARA is the first biologic therapy for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses.

In May 2016, Takeda Canada, received Health Canada approval for biologic treatment ENTYVIO (vedolizumab) to treat adults with moderate to severely active Crohn’s disease (CD), the most common form of inflammatory bowel disease, offering an important new option for patients.



Global Crohn’s Disease Therapeutics Market – Geographical Analysis

The global Crohn’s disease therapeutics market is segmented into North America, Europe, Asia Pacific, South America and the Middle East and Africa.

North America is dominating the global Crohn’s Disease therapeutic market, due to high incidence rate of the disease and notable increase in the regulatory approval of crohn’s disease therapeutics in the recent years.

According to the Centers for Disease Control and Prevention, the prevalence of Crohn disease in North America was 319 per 100,000 persons, whereas in Europe, it was 322 per 100,000 persons in 2017.

Few of the recent drug approvals include –

In October 2018, Sandoz, a Novartis division and one of prominent players in the biosimilars market, received the FDA approval for its biosimilar, Hyrimoz (adalimumab-adaz). The product received FDA approval for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) in patients four years of age and older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), adult Crohn's disease (CD), ulcerative colitis (UC) and plaque psoriasis (Ps).

In November 2016, AbbVie, a global biopharmaceutical company, received the FDA approval for risankizumab (ABBV-066; formerly BI 655066) for the investigational treatment of Crohn's disease in pediatric patients.



Global Crohn’s Disease Therapeutics Market – Competitive Analysis

The launch of new Crohn’s disease drugs and strategic collaborations by the companies for research and development activities for Crohn’s disease drug is driving the global Crohn’s disease therapeutics market.

For instance, in July 2017, Merck introduced RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) in U.S. RENFLEXIS is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease.

In October 2017, Genomics Medicine Ireland Ltd., has collaborated with leading Dublin hospitals St. Vincent’s University Hospital / University College Dublin Clinical Research Centre and Tallaght Hospital which aims to identify genetic markers that can help diagnose, predict disease severity and identify personalized treatments for people with Inflammatory Bowel Disease (IBD). There are two major forms of IBD, Crohn’s disease (CD) and Ulcerative colitis (UC).

The major players include AbbVie Inc., Allergan, Inc., Bayer AG, Bristol-Myers Squibb, Boehringer Ingelheim GmbH, Hoffmann-La Roche, Eli Lilly and Co., GlaxoSmithKline Plc, Janssen Biotech, Inc., Johnson & Johnson, Novartis International AG, Pfizer Inc., Sanofi, and Takeda Pharmaceutical Company Limited.

 

Reasons for purchasing the report?

  • Visualize the composition of Crohn’s disease market across each indication, regarding type and treatment options, highlighting the critical commercial assets and players.
  • Identify commercial opportunities in Crohn’s disease market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of the market – level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for critical products of all major market players

 

Who can benefit from this report?

  • Equipment Suppliers/ Buyers
  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

1.  Global Crohn’s Disease Therapeutic Market Methodology and Scope

1.1. Research Methodology

1.2.Research Objective and Scope of the Report


2. Global Crohn’s Disease Therapeutic Market – Market Definition and Overview


3. Global Crohn’s Disease Therapeutic Market – Executive Summary

3.1.Market Snippet by Drug Class

3.2. Market Snippet by Distribution Channel

3.3. Market Snippet by Region

3.4. DataM CLO Scenario


4. Global Crohn’s Disease Therapeutic Market – Market Dynamics

4.1.Market Impacting Factors

4.1.1. Drivers

4.1.1.1. Increasing diagnosed prevalent cases of inflammatory bowel disease

4.1.1.2. Increasing demand for biologics to cure bowel disorders

4.1.2. Restraints

4.1.2.1. Lack of early diagnosis

4.1.2.2. High cost of treatment

4.1.3. Opportunity

4.1.3.1.   Increasing Pipeline products

4.1.4. Impact Analysis


5.  Global Crohn’s Disease Therapeutic Market – Industry Analysis

5.1.  Porter's Five Forces Analysis

5.2. Supply Chain Analysis

5.3. Regulatory Analysis

5.4. Epidemiology


6. Global Crohn’s Disease Therapeutic Market – By Drug Class

6.1.1.  Introduction

6.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment

6.1.3. Market Attractiveness Index, By Drug Class Segment

6.2. Anti-diarrheal

6.2.1. Introduction

6.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

6.3. Anti-inflammatory drugs

6.4. Immunosuppressors

6.5. Antibiotics

6.6. Biologics

6.7. Pain relievers    


7.  Global Crohn’s Disease Therapeutic Market – By Distribution Channel Introduction

7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

7.1.2. Market Attractiveness Index, By Distribution Channel

7.2. Hospital Pharmacies

7.2.1. Introduction

7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

7.3. Retail Pharmacy

7.4. Online Pharmacy


8. Global Crohn’s Disease Therapeutic Market – By Region

8.1.Introduction

8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

8.1.2. Market Attractiveness Index, By Region

8.2. North America

8.2.1. Introduction

8.2.2. Key Region-Specific Dynamics

8.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

8.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

8.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

8.2.5.1. U.S.

8.2.5.2. Canada

8.2.5.3. Mexico

8.3. Europe

8.3.1. Introduction

8.3.2. Key Region-Specific Dynamics

8.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

8.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

8.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

8.3.5.1. Germany

8.3.5.2. U.K.

8.3.5.3. France

8.3.5.4. Italy

8.3.5.5. Spain

8.3.5.6. Rest of Europe

8.4. South America

8.4.1. Introduction

8.4.2. Key Region-Specific Dynamics

8.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

8.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

8.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

8.4.5.1. Brazil

8.4.5.2. Argentina

8.4.5.3. Rest of South America

8.5. Asia Pacific

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

8.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

8.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

8.5.5.1. China

8.5.5.2. India

8.5.5.3. Japan

8.5.5.4. Australia

8.5.5.5. Rest of Asia Pacific

8.6. Middle East and Africa

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class

8.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel


9. Global Market – Competitive Landscape

9.1.Competitive Scenario

9.2. Market Positioning/Share Analysis

9.3. Mergers and Acquisitions Analysis


10.Company Profiles

10.1. AbbVie Inc.*

10.1.1. Company Overview

10.1.2. Product Portfolio and Description

10.1.3. Key Highlights

10.1.4. Financial Overview

10.2. Allergan, Inc.

10.3. Bayer AG

10.4. Bristol-Myers Squibb

10.5. Boehringer Ingelheim GmbH

10.6. Hoffmann-La Roche

10.7. Eli Lilly and Co.

10.8. GlaxoSmithKline Plc

10.9. Novartis International AG

10.10. Johnson & Johnson

10.11. Janssen Biotech, Inc.

10.12. Pfizer Inc.

10.13. Sanofi

10.14. Takeda Pharmaceutical Company Limited


11. Global Crohn’s Disease Therapeutic Market – Premium Insights


12.Global Crohn’s Disease Therapeutic Market – DataM

12.1. Appendix

12.2. About Us and Services

12.3. Contact Us

LIST OF TABLES

Table 1           Global Crohn’s Disease Therapeutic Market Value, By Drug Class, 2018,2022 & 2026 ($ Million)

Table 2          Global Crohn’s Disease Therapeutic Market Value, By Distribution Channel, 2018,2022 & 2026 ($ Million)

Table 3          Global Crohn’s Disease Therapeutic Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 4          Global Crohn’s Disease Therapeutic Market Value, By Drug Class, 2018,2022 & 2026 ($ Million)

Table 5          Global Crohn’s Disease Therapeutic Market Value, By Drug Class, 2017-2026 ($ Million)

Table 6          Global Crohn’s Disease Therapeutic Market Value, By Distribution Channel, 2018,2022 & 2026 ($ Million)

Table 7          Global Crohn’s Disease Therapeutic Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 8          Global Crohn’s Disease Therapeutic Market Value, By Region, 2018,2022 & 2026 ($ Million)

Table 9          Global Crohn’s Disease Therapeutic Market Value, By Region, 2017-2026 ($ Million)

Table 10        North America Crohn’s Disease Therapeutic Market Value, By Drug Class, 2017-2026 ($ Million)

Table 11         North America Crohn’s Disease Therapeutic Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 12        North America Crohn’s Disease Therapeutic Market Value, By Country, 2017-2026 ($ Million)

Table 13        South America Crohn’s Disease Therapeutic Market Value, By Drug Class, 2017-2026 ($ Million)

Table 14        South America Crohn’s Disease Therapeutic Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 15         South America Crohn’s Disease Therapeutic Market Value, By Country, 2017-2026 ($ Million)

Table 16        Europe Crohn’s Disease Therapeutic Market Value, By Drug Class, 2017-2026 ($ Million)

Table 17         Europe Crohn’s Disease Therapeutic Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 18        Europe Crohn’s Disease Therapeutic Market Value, By Country, 2017-2026 ($ Million)

Table 19        Asia-Pacific Crohn’s Disease Therapeutic Market Value, By Drug Class, 2017-2026 ($ Million)

Table 20        Asia-Pacific Crohn’s Disease Therapeutic Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 21        Asia-Pacific Crohn’s Disease Therapeutic Market Value, By Country, 2017-2026 ($ Million)

Table 22        Middle East & Africa Crohn’s Disease Therapeutic Market Value, By Drug Class, 2017-2026 ($ Million)

Table 23        Middle East & Africa Crohn’s Disease Therapeutic Market Value, By Distribution Channel, 2017-2026 ($ Million)

Table 24        AbbVie Inc.: Overview

Table 25        AbbVie Inc.: Product Portfolio

Table 26        AbbVie Inc.: Key Developments

Table 27        Allergan, Inc.: Overview

Table 28        Allergan, Inc.: Product Portfolio

Table 29        Allergan, Inc.: Key Developments

Table 30        Bayer AG: Overview

Table 31        Bayer AG: Product Portfolio

Table 32        Bayer AG: Key Developments

Table 33        Bristol-Myers Squibb: Overview

Table 34        Bristol-Myers Squibb: Product Portfolio

Table 35        Bristol-Myers Squibb: Key Developments

Table 36        Boehringer Ingelheim GmbH: Overview

Table 37        Boehringer Ingelheim GmbH: Product Portfolio

Table 38        Boehringer Ingelheim GmbH: Key Developments

Table 39        Hoffmann-La Roche: Overview

Table 40        Hoffmann-La Roche: Product Portfolio

Table 41        Hoffmann-La Roche: Key Developments

Table 42        Eli Lilly and Co.: Overview

Table 43        Eli Lilly and Co.: Product Portfolio

Table 44        Eli Lilly and Co.: Key Developments

Table 45        GlaxoSmithKline Plc: Overview

Table 46        GlaxoSmithKline Plc: Product Portfolio

Table 47        GlaxoSmithKline Plc: Key Developments

Table 48        Janssen Biotech, Inc.: Overview

Table 49        Janssen Biotech, Inc.: Product Portfolio

Table 50        Janssen Biotech, Inc.: Key Developments

Table 51         Johnson & Johnson: Overview

Table 52        Johnson & Johnson: Product Portfolio

Table 53        Johnson & Johnson: Key Developments


LIST OF FIGURES


Figure 1         Global Crohn’s Disease Therapeutic Market Share, By Drug Class, 2018 & 2026 (%)

Figure 2        Global Crohn’s Disease Therapeutic Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 3        Global Crohn’s Disease Therapeutic Market Share, By Region, 2018 & 2026 (%)

Figure 4        Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 5        Global Crohn’s Disease Therapeutic Market Y-o-Y Growth, By Drug Class, 2018-2026 (%)

Figure 6        Anti-diarrheal: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 7        Anti-inflammatory drugs: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 8        Immunosuppressors: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 9        Antibiotics: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 10      Biologics: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 11       Pain relievers: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 12      Global Crohn’s Disease Therapeutic Market Y-o-Y Growth, By Distribution Channel, 2018-2026 (%)

Figure 13      Hospitals: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 14      Retail Pharmacy: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 15       Online Pharmacy: Global Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 16      Global Crohn’s Disease Therapeutic Market Y-o-Y Growth, By Region, 2018-2026 (%)

Figure 17       North America Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 18      North America Crohn’s Disease Therapeutic Market Share, By Drug Class, 2018 & 2026 (%)

Figure 19      North America Crohn’s Disease Therapeutic Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 20      North America Crohn’s Disease Therapeutic Market Share, By Country, 2018 & 2026 (%)

Figure 21      South America Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 22      South America Crohn’s Disease Therapeutic Market Share, By Drug Class, 2018 & 2026 (%)

Figure 23      South America Crohn’s Disease Therapeutic Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 24      South America Crohn’s Disease Therapeutic Market Share, By Country, 2018 & 2026 (%)

Figure 25      Europe Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 26      Europe Crohn’s Disease Therapeutic Market Share, By Drug Class, 2018 & 2026 (%)

Figure 27      Europe Crohn’s Disease Therapeutic Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 28      Europe Crohn’s Disease Therapeutic Market Share, By Country, 2018 & 2026 (%)

Figure 29      Asia-Pacific Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 30      Asia-Pacific Crohn’s Disease Therapeutic Market Share, By Drug Class, 2018 & 2026 (%)

Figure 31      Asia-Pacific Crohn’s Disease Therapeutic Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 32      Asia-Pacific Crohn’s Disease Therapeutic Market Share, By Country, 2018 & 2026 (%)

Figure 33      Middle East & Africa Crohn’s Disease Therapeutic Market Value, 2017-2026 ($ Million)

Figure 34      Middle East & Africa Crohn’s Disease Therapeutic Market Share, By Drug Class, 2018 & 2026 (%)

Figure 35      Middle East & Africa Crohn’s Disease Therapeutic Market Share, By Distribution Channel, 2018 & 2026 (%)

Figure 36      AbbVie Inc.: Financials

Figure 37      Allergan, Inc.: Financials

Figure 38      Bayer AG: Financials

Figure 39      Bristol-Myers Squibb: Financials

Figure 40      Boehringer Ingelheim GmbH: Financials

Figure 41      Hoffmann-La Roche: Financials

Figure 42      Eli Lilly and Co.: Financials

Figure 43      GlaxoSmithKline Plc: Financials

Figure 44      Janssen Biotech, Inc.: Financials

Figure 45      Johnson & Johnson: Financials

Buy This Report



To get the free report sample tailored to your requirements

Could not find what you need?

Quick Fact: 7 of 10 customers Tailor their reports

DMI Cognizance Expertise

Massive Repository

10-year historic data for 1000+ markets

Association Networks

Ground-Zero understanding of the market with inputs from relevant industry association members

First Hand Understanding

Tailored interviews with manufacturers, buyers, sellers, distributers and retailers for five-frame understanding of the market

360 Web Research

Analysis of publicly available white label papers, news announcements, press releases, financial reports and reliable paid consulting data

Star Expert Review

7-step data formulation for market analysis and forecasts, under thorough scrutiny of industry-specific consultants with over 20+ years of expertise

INSTANT DELIVERY - 20% OFF

Copyright © 2019 DataM Intelligence. All Rights Reserved

Designed and Developed by -Montaigne Labs